

## **Profile of patients treated with intravitreal anti-vascular endothelial growth factor injections in Bhutan: a 3-year national survey**

Bhim B. Rai<sup>1,2</sup>, Deepa Rai<sup>3</sup>, Ted Maddess<sup>1</sup>

<sup>1</sup>John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.

<sup>2</sup>Department of Ophthalmology, JDW National Referral Hospital, Thimphu, Bhutan.

<sup>3</sup>Warrigal Aged Care Facility, Calwell, ACT, Australia.

### **Corresponding Author**

Dr. Bhim Bahadur Rai

Building 131, Garran Road, John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601.

Email: [bhim.rai@anu.edu.au](mailto:bhim.rai@anu.edu.au)

Phone number: +61 2 61259253

**AUTHOR ORCID IDs:** Rai 0000 0003 0748 4581, Maddess 0000-0003-4591-3658.

AUTHOR EMAIL:

Bhim Rai: [bhim.rai@anu.edu.au](mailto:bhim.rai@anu.edu.au)

Deepa Rai: [nana.raee@yahoo.com](mailto:nana.raee@yahoo.com)

Ted Maddess: [ted.maddess@anu.edu.au](mailto:ted.maddess@anu.edu.au)

**Running title:** Anti-VEGF injections in Bhutan

**Words:** 2,868

**Figures:** Nil

**Tables:** 2

ABSTRACT (285 WORDS)

1 Purpose: Ocular vascular diseases are common causes of visual impairment and blindness,  
2 for which intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the  
3 first-line therapy. Current study describes the profile of patients receiving intravitreal anti-  
4 VEGF injections in Bhutan. This is the first study of its kind to inform the national health  
5 policy.

6 **Methods:** For this retrospective study, we reviewed the surgical registers of the vitreoretinal  
7 unit across Bhutan over three years. Patient demography, clinical findings, diagnostic tests  
8 performed, and diagnoses or indications for intravitreal anti-VEGF injections were logged. A  
9 descriptive analysis was performed.

10 **Results:** A total of 381 patients received intravitreal anti-VEGF injections in the operating  
11 theatres as mandated by the national guidelines. The majority of patients were males (230,  
12 60.4%). The mean age was  $65.2 \pm 13.5$  years, ranging from 13 to 90 years, and a median of  
13 69 years. Majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception  
14 (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for anti-  
15 VEGF injection was neovascular AMD (168 cases, 42.2%), followed by retinal vein  
16 occlusion (132 cases, 34.6%), diabetic macular oedema and retinopathy (50 cases, 13.1%),  
17 and myopic choroidal neovascular membrane (11 cases, 0.03%).

18 **Conclusions:** Bhutan faces both economic and geographic challenges, on top of limited  
19 human resources for managing vitreoretinal diseases. With an ever-increasing load of  
20 vitreoretinal diseases, and systemic diseases like diabetes and hypertension, there is a need to  
21 improve vitreoretinal services. Regular vitreoretinal services are provided only at the national  
22 referral hospital located in the north-west. For successful management, an effective

*Anti-VEGF injections in Bhutan*

- 23 community screening program, right referrals, and proper transport facilities must go hand-
- 24 in-hand, and or extend regular vitreoretinal services to regional referral hospitals.
- 25 **Key words:** Anti-VEGF; Bhutan retinal diseases, diabetic macular oedema; intravitreal
- 26 injection; neovascular AMD; retinal vein occlusion.

## 28 INTRODUCTION

29 Vascular diseases such as neovascular age-related macular degeneration (nAMD), diabetic  
30 macular oedema (DMO) and diabetic retinopathy (DR), and retinal vein occlusion (RVO) are  
31 the major causes of visual impairment and loss of central vision throughout the world (1).  
32 Previously refractory cases were treated with intravitreal injection of corticosteroid  
33 triamcinolone acetonide and dexamethasone (2). However, these agents were associated with  
34 multiple ocular side effects such as cataract and intraocular pressure spikes (2). The  
35 pathogeneses of many such diseases are multifactorial. Both inflammatory mediators and  
36 vasogenic mediators, such as vascular endothelial growth factors (VEGFs), are activated and  
37 create disruption of the retina (3, 4). As the inner blood-retinal barrier breaks down, fluids  
38 and proteins leak into the retina. This leakage creates oedema of the macula and thereby  
39 decreases the retinal transparency (2-5). To counter this effect, anti-VEGFs came into clinical  
40 use with much promise. It also earned the name of a *one day wonder drug* for the fast  
41 resolution of DMO following intravitreal injection of ranibizumab (6). Among anti-VEGFs,  
42 bevacizumab (AVASTIN, Genentech, Inc.,) was the first agent to be used off-label in 2005.  
43 Subsequently, multiple anti-VEGF agents such as pegaptanib sodium (Eyestech/OSI  
44 Pharmaceuticals, New York, NY, USA), ranibizumab (Lucentis™, Genentech, Inc., South  
45 San Francisco, CA, USA and Novartis Pharma AG, Basel, Switzerland), aflibercept (VEGF-  
46 trap eye, Eylea™, Regeneron Pharmaceuticals, Inc., and Bayer Pharma AG, Berlin,  
47 Germany), brolucizumab (Beovu™, Novartis Pharma AG, Basel, Switzerland), and faricimab  
48 have been developed for the management of various ocular vascular diseases (7-11).  
49 Although all these agents are used, only pegabtanib, ranibizumab, brolucizumab, aflibercept,  
50 and faricimab are approved for use in ophthalmological disorders (11-13). Ranibizumab,  
51 bevacizumab and brolucizumab specifically target VEGF-A activity, while aflibercept has a  
52 broader spectrum of action – VEGF-A, as well as other VEGF family ligands such as VEGF-

*Anti-VEGF injections in Bhutan*

53 B, placental growth factor-1 (PIGF-1) and placental growth factor-2 (PIGF-2) (14, 15).  
54 Faricimab is a new and the first bispecific monoclonal antibody for intravitreal use  
55 neutralising both VEGF and angiopoietin-2/tie-2/ pathway(16). Due to the prolonged activity,  
56 faricimab allows extended intervals between injections of up to three or four months in  
57 nAMD and DMO patients, which can be a significant benefit for patients and are an  
58 alternative to implanted drug delivery systems (17, 18). The aim of the current study was to  
59 report on the profile of patients treated with intravitreal anti-VEGFs injections for  
60 ophthalmological diseases in Bhutan. Since this is the first study of this kind in the country  
61 and the results have impacts for policy making in Bhutan and other developing countries in  
62 the region.

63 **METHODS**

64 **Study design and Ethics**

65 This was a retrospective, case series study approved by the Research Ethics Board of Health  
66 (REBH) (REBH/Approval/2016/083), Ministry of Health, Royal Government of Bhutan,  
67 Thimphu, Bhutan. This study adhered to the principles of the Declaration of Helsinki.  
68 Informed consent was waived by REBH because this retrospective study collected only de-  
69 identified data.

70 **Setting**

71 In Bhutan the Jigme Dorji Wangchuck (JDW) national referral hospital is the only apex  
72 national referral and teaching hospital with subspecialty eye-care services. Regular  
73 vitreoretinal surgical and interventional services in the country are provided only at the JDW  
74 national referral hospital. All such vitreoretinal patients across the country are referred there  
75 for management. Occasionally the vitreoretinal surgeon visits Eastern Regional Referral  
76 Hospital (ERRH) in Mongar and Central Regional Referral Hospital (CRRH) in Gelephu

77 when the treatment is provided there. The sites for the current study included JDW national  
78 referral hospital (in the main), and ERRH and CRRH.

## 79 **Participants**

80 All the patients who received intravitreal anti-VEGF injections in the operation theatres at the  
81 JDW national referral hospital, ERRH and CRRH over three years (01 May 2013 until 30  
82 April 2016) were included. The national guidelines mandate that intravitreal injections should  
83 be administered only in operating theatres with proper aseptic measures. The demographic  
84 characteristics of patients receiving the anti-VEGF injection and the vitreoretinal disease  
85 pattern represent the entire citizenry.

## 86 **Clinical Examination and data collection**

87 The clinical workup in the out-patient department (OPD) included taking detailed medical  
88 histories of presenting symptoms and diseases, associated systemic diseases, and prior  
89 surgical or laser interventions done. Best corrected visual acuity (BCVA) at presentation was  
90 measured using a Snellen chart, and Tumbling E for illiterate patients. Intraocular pressure  
91 was measured by Goldmann applanation tonometry or an iCare tonometer, and the anterior  
92 and posterior segments were examined under slit-lamp biomicroscopy (BM 900, Haag-Streit,  
93 Switzerland) and 90D bio-microscopy. The funduscopy findings were confirmed by  
94 binocular indirect ophthalmoscope (Model 125, Welch Allyn, USA). Macular and retinal  
95 nerve fibre (RNFL) scans were measured using a Spectral Domain Optical Coherence  
96 Tomography (OCT) (Cirrus-HD 4000, Carl Zeiss Germany). Fundus photographs were taken  
97 by a VISUCAM-524 (Carl Zeiss, Germany). Fundus fluorescein angiograms (FFA) were  
98 performed when needed to confirm occult diseases. A B-ultra sonogram scan was done when  
99 necessary (Sonomed Escalon, Model: VUPAD A/B, USA).

*Anti-VEGF injections in Bhutan*

100 For the current study, the patient register maintained in the vitreoretinal operational theatre  
101 was reviewed for the data collection. The data collected included demographic information  
102 such as age and gender, residential settings, BCVA, diagnostic tests performed, and diagnosis  
103 or indications for anti-VEGF injections.

104 **Diagnostic tests**

105 OCT was performed universally on all cases who have received intravitreal anti-VEGF  
106 injections. This was an appropriate diagnostic tool to diagnose nAMD, RVO, DMO, myopic  
107 choroidal neovascular membrane (mCNVM), cystoid macular oedema, central serous  
108 chorioretinopathy and vitreomacular tractions. Polypoidal choroidal vasculopathy (PCV) is  
109 best diagnosed via its characteristic nodular dilatations arising from neovascular networks  
110 that ramify mainly in the subretinal pigment epithelial space on indocyanine green  
111 angiography.(19, 20) However, in the current study the PCV was mainly diagnosed based on  
112 the OCT findings such as sharp-peaked retinal pigment epithelial detachment (RPED),  
113 subretinal pigment detachment ring-like lesion, multilobular RPED, double-layer sign or  
114 shallow, irregular retinal pigment epithelium elevation, thick choroid with dilated Haller's  
115 layer vessels, and predominance of subretinal fluid. Other suggestive findings with the  
116 coloured fundus photographs were extensive subretinal haemorrhage, and orange  
117 nodules.(21) The FFA was performed only in difficult or occult cases.

118 **Anti-VEGF injections**

119 Most of the time, a 4 ml vial containing 100 mg bevacizumab was procured. The patients  
120 needing intravitreal anti-VEGF injections were pooled for a scheduled injection day, when a  
121 vial was opened and dosing formulation done at 1.25 mg per 0.05 ml, or 2.5 mg per 0.1 ml in  
122 tuberculin syringes with 30G needles. So a single vial would benefit 20 to 25 pooled patients.  
123 This approach was practised for economic reasons. The anti-VEGF dosing formulations and  
124 intravitreal injections were performed under aseptic measures in the operating theatres.

125 Injections into the bilateral eyes in the same sitting was not performed to avoid complications,  
126 notably endophthalmitis.

## 127 RESULTS

### 128 **Demographic characteristics**

129 A total of 381 patients received intravitreal anti-VEGF injections over the study period. The  
130 majority of patients (230, 60.4%) were males, and others females (151, 39.6%). The mean  
131 age at presentation was  $65.2 \pm 13.5$  years (ranging from 13 to 90 years), modal year of 70  
132 years, and median 69 years.

### 133 **Visual acuity**

134 BCVA at presentation was recorded in the vitreoretinal unit OPD register and the patient  
135 personal files. For the current study we referred to the surgical register maintained in the  
136 operating theatre, where BCVA for all cases were not recorded. As a result, the data on  
137 BCVA was not available (NA) in 85 cases (Table 1). Among those with BCVA data  
138 available, majority of the eyes treated with anti-VEGF injections had BCVA of less than 3/60  
139 to only perception of light (PL), labelled as blindness according to World Health  
140 Organisation (WHO) classification of visual impairment, in the treated eyes (117 cases, 30.7)  
141 (22). We could not ascertain if they were legally blind with this because we did not have the  
142 data on BCVA of their fellow eyes. The details of the BCVA are shown in **Table 1**.

143 **Table 1.** Best corrected visual acuity at presentation

<i>Visual acuity based on WHO classification of blindness</i>	<i>No. of eyes</i>	<i>Percentage</i>
$\geq 6/18$	21	5.5
$< 6/18 - 6/60$	107	28.1
$< 6/60 - 3/60$	51	13.4
$< 3/60 - PL^*$	117	30.7
NA <sup>†</sup>	85	22.3
NPL <sup>^</sup>	0	0



<i>Total</i>	381	100
--------------	-----	-----

144 NA†: Data not available; NPL^: No perception of light; PL\*: Perception of light.

145 **Intravitreal anti-VEGF injections**

146 nAMD was the most common indication for the intravitreal anti-VEGF injection, accounted  
 147 for 168 cases (44.2%). This was followed by RVO in 132 cases (34.6%). Within the RVO  
 148 subgroup, branch RVO (BRVO) was the most common subgroup with 70 cases (53.0%),  
 149 followed by central RVO (CRVO) in 55 cases (41.7%), and hemi-retinal BRVO (HRBRVO)  
 150 in 7 cases (5.3%). Only 50 cases (13.1%) receiving anti-VEGF injections had DR or DMO,  
 151 11 cases (0.03%) had mCNVM, and 6 cases (0.02%) had PCV. Other indications for anti-  
 152 VEGF injections are shown in **Table 2**.

153 **Table 2: Indications of anti-VEGF Injection**

<i>Indications</i>	<i>Number of cases</i>	<i>Percentage</i>
<i>Neovascular AMD</i>	168	44.2
<i>Total Retinal Vein Occlusion</i>	132	34.6
<i>Branch Retinal Vein Occlusion (BRVO)</i>	70	53.0
<i>Central Retinal Vein Occlusion (CRVO)</i>	55	41.7
<i>Hemi-retinal BRVO (HRBRVO)</i>	7	5.3
<i>Diabetic Macular Oedema</i>	50	13.1
<i>Myopic CNVM (mCNVM)</i>	11	0.03
<i>Polypoidal Choroidal Vasculopathy (PCV)</i>	6	0.02
<i>Neovascular Glaucoma</i>	4	0.01
<i>Others*</i>	10	0.03
<i>Total</i>	<b>381</b>	<b>100.0</b>

154 2 cases of injection were excluded as the indications were not recorded.

155 \*Others include Cystoid macular oedema, Central serous chorioretinopathy and Vitreomacular traction

156 **DISCUSSION**

157 To summarise the vital results, 30.7% of the study eyes were legally blind, 13.4% had severe  
 158 visual impairment (VI) and 28.1% has moderate VI as per the WHO classification of VI (22).

*Anti-VEGF injections in Bhutan*

159 nAMD was the most common indication for intravitreal anti-VEGF injections, followed by  
160 RVO, DMO/DR, mCNVM, PCV, and neovascular glaucoma.

161 A study on the pattern and presentation of vitreoretinal diseases in Bhutan in the same period  
162 reported that majority of patients were males, 1544/2913 (23). That is somewhat lower than  
163 the rate seen here ( $p=0.048$ ,  $\chi^2=3.90$ ). A meta-analysis of eye surgical services in developing  
164 countries has shown that females receive fewer surgical or interventional services than the  
165 males (24), as was seen with receiving anti-VEGF injections in the current study. The  
166 national vitreoretinal unit was established in Bhutan only in early 2012 (25), Prior to that,  
167 vitreoretinal cases were referred to India or Nepal for treatment. Most patients were reluctant  
168 to go out of the country for surgery, however, because of the communication gap in foreign  
169 lands. This partly encouraged some patients to seek to traditional or indigenous methods of  
170 healing. Some even sought to local healers or witchcraft practice with false hope, resulting in  
171 irreversible loss of vision and even loss of eyes, while most cases did not receive any  
172 treatment and accepted it as their destiny.

173 AMD was reported as the fourth most common vitreoretinal disease in Bhutan, next to  
174 hypertensive retinopathy, refractive errors referred for retinal evaluation, and DR or clinically  
175 significant macular oedema (CSMO) (23). So it is apparent that intravitreal anti-VEGF  
176 injection was most commonly administered to nAMD cases. Another study on the profile of  
177 AMD in Bhutan reported that half of AMD cases were in advance stages needing treatment,  
178 and one-third of those with advanced diseases already had disciform scar at their first  
179 presentation (26). Similarly, the drop-out rates for follow-up are high. The reason for such  
180 late presentation and poor follow-up or medical adherence are many. First, lack of knowledge  
181 of the general public on diseases and treatment options available. Secondly, lack of  
182 accessibility to services – the regular vitreoretinal service is provided only at the JDW  
183 national referral hospital located in the north-west part of the country and the patients from

*Anti-VEGF injections in Bhutan*

184 the central and eastern regions have to travel all the way against difficult terrain, poor road  
185 conditions and transport limitations to avail the treatment. Other reasons include poor referral  
186 system, communication gap between the peripheral and referral hospitals, and negative  
187 influence of the local healers.

188 Co-existent hypertension and diabetes mellitus, the complications of which result to many  
189 ocular vascular diseases, is common in Bhutan (27). WHO has reported that 28% of total  
190 mortality in Bhutan was due to cardiovascular disease, and another 17% due to other non-  
191 communicable diseases (28). For these morbidities, the risk factors include harmful use of  
192 alcohol, high salt intake, unhealthy diet, physical inactivity, and tobacco use (29).

193 Considering hypertensive retinopathy and diabetes mellitus as risk factors for RVO (30), and  
194 both being common among the Bhutanese population, RVO cases received the second  
195 highest number of anti-VEGF injections. Similarly, RVO cases also was the second most  
196 common indication to receive retinal laser therapy in the country, second only to DR/DMO  
197 (31). Only 50 cases (13.1% of all anti-VEGF injections) received anti-VEGF injection in the  
198 study population although DR and DMO was the third most common vitreoretinal disease in  
199 Bhutan, and second most common in a similar study conducted in Nepal (32). This is because  
200 only the central DMO, and DMO nasal to the fovea, were treated with anti-VEGF injection.  
201 Very severe DR not responding to panretinal photocoagulation (PRP) were also first treated  
202 with the anti-VEGF injections to reduce retinal oedema after which PRP was performed  
203 successfully. Commonly, the DR cases were managed with PRP to such a rate that PRP was  
204 the most common type of retinal laser therapy performed in Bhutan (31). Off-centre DMO  
205 (except DMO nasal to the fovea) was managed with focal, grid or modified grid laser  
206 therapies. An unpublished study (under review with the Japanese J of Ophthalmology) has  
207 reported that 25.6% of diabetes patients presented 5-10 years after diagnosis, 19.9% after 10-  
208 20 years and 2.3% presented only after 20 years for the first time for their eye/retinal check-

*Anti-VEGF injections in Bhutan*

209 up. The study also reported that 12.5% of DR cases had proliferative DR at their first  
210 presentation for retinal evaluation.

211 Although the moderate to high myopic cases referred for retinal evaluation was the second  
212 most common reason for attending vitreoretinal clinics in Bhutan, next to hypertensive  
213 retinopathy (23), only a small percentage of anti-VEGF injections was given to cases of  
214 myopic CNVM (mCNVM). This is because the prevalence of mCNVM among the study  
215 group of myopia was only 0.4% (33). Other studies have reported that mCNVM occurs in  
216 approximately 5-10% of highly myopic patients, and 0.04-0.05% of the general population  
217 (34, 35). PCV is common chorioretinal disorder among the Asian populations.(36) It has been  
218 estimated that up to 50% of nAMD cases among the Asians are of the PCV subtype, whereas  
219 this proportion among the white populations is estimated to range between 10% and 20% (37,  
220 38). In Bhutan, 8.1% of advanced AMD were comprised of PCV, and among them 73.7% of  
221 them (14/19 cases) were younger than 50 years (26). This is highly concerning for a country  
222 like Bhutan with a small reserve of working age population and limited human resources. Yet  
223 only six of nineteen cases of PCV received anti-VEGF treatment, that is, 68.4% of them did  
224 not receive treatment. There is fear that they may turn up later with worsened disease not  
225 being amenable to the treatment. With these concerns, it was also deliberated that community  
226 screening of AMD along with PCV cases might be helpful in Bhutan (39). However, until  
227 today, it seems there are no large-scale screening programs for AMD like those that exist for  
228 DR and retinopathy of prematurity.

229 It is common that younger patients have poor medical adherence (40). So the treating  
230 physicians and the healthcare professionals have to give extra effort to teach them about the  
231 disease and ensure the importance of timely medications. Additionally, the general  
232 population in Bhutan are illiterate and have poor knowledge of diseases and treatment  
233 options. Although health education is provided at all levels of healthcare centres in Bhutan

*Anti-VEGF injections in Bhutan*

234 there is need to improve the program. It may be effective to disseminate health advocacy  
235 information in the local languages or dialects so the common people are able to understand  
236 the message. Involving local leaders and local government bodies may prove more effective.  
237 Broadcasting the materials through the national television channels, or even targeting the  
238 younger generations through the mobile phone applications they use, may be helpful. For  
239 regionally balanced delivery of the services, Bhutan needs to extend its regular vitreoretinal  
240 services to the ERRH and CRRH, or at least improve community screening and effective  
241 referral system. New approaches to screening and management of the AMD cases may allow  
242 for expansion of high-quality convenient care and increasing patient coverage (41). The  
243 public transport system in Bhutan is challenged by difficult terrain, poor quality of roads and  
244 infrequent services. Additionally, it is interrupted during monsoon season by landslides,  
245 falling boulders and swollen rivers and streams, and by snowfall during winters. Therefore,  
246 the proper arrangement of transport facilities for the patients is a must for successful  
247 screening and referral program. For referrals too, a concept of *right referral* must be  
248 practised. Only the patients needing to be seen by the retinal specialist and interventions at  
249 the national referral hospital should be referred. If patients are referred only to be told that no  
250 further action required after taking a difficult journey, then such improper referral will  
251 certainly have negative impact on the program. Tactfully, Bhutan also needs to lower the  
252 influence of local healers and encourage people to visit hospitals while having health issues.  
253 Although Bhutan still struggles to provide basic medical provision and low-cost treatment, it  
254 may be worth to identify patients who are not compliant to follow up or adherent to  
255 medication and provide longer acting anti-VEGF treatment such as faricimab, which can  
256 extend the intervals between successive drug administration by 4 to 6 months (17, 18).

257 This study is limited by being a retrospective study and a small number of study subjects.  
258 We did not have visual acuity at presentation for 85 cases (22.3%). Being a cross-sectional

259 study, we also did not follow up the patients to understand the outcome of the anti-VEGF  
260 treatment. We have a plan to conduct a prospective study overcoming all the limitations of  
261 the current study.

## 262 CONCLUSIONS

263 There is need to improve the vitreoretinal services in Bhutan. Currently regular vitreoretinal  
264 service is provided only at the JDW national referral hospital, so there is high risk that the  
265 patients from the eastern and central regions miss out on the treatment and regular follow up.  
266 So regular services need to be expanded to the eastern and central regional referral hospitals.  
267 Secondly, vitreoretinal diseases secondary to systemic diseases such as hypertension and  
268 diabetes are common. There is an urgent need for strategic control and management of non-  
269 communicable diseases and prevent blindness and visual impairment from their  
270 complications.

## 271 DECLARATIONS

### 272 **Conflict of interest**

273 Author BBR declares that he has no conflict of interest. Author DR declares that she has no  
274 conflict of interest. Author TM declares that he has no conflict of interest.

### 275 **Funding**

276 The funders had no role in study design, data collection and analysis, decision to publish, or  
277 preparation of the manuscript.

278 **Ethical approval, Informed Consent and Consent for Publication**

279 The study was approved by the Research Ethics Board of Health (REBH)

280 (REBH/Approval/2016/083), Ministry of Health, Royal Government of Bhutan, and was

281 conducted as per the REBH guidelines and tenets of the Declaration of Helsinki. The consent

282 was waived by REBH as the retrospective study collected only the de-identified data.

283 **Availability of data and material**

284 The data and material are available with the corresponding author.

## 286 REFERENCES

- 287 1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence  
288 and major risk factors of diabetic retinopathy. *Diabetes Care*. 2012;35(3):556-64.
- 289 2. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? *Curr*  
290 *Diab Rep*. 2012;12(4):364-75.
- 291 3. Noma H, Yasuda K, Shimura M. Cytokines and the Pathogenesis of Macular Edema in Branch  
292 Retinal Vein Occlusion. *J Ophthalmol*. 2019;2019:5185128.
- 293 4. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. *Pharmacol*  
294 *Rep*. 2006;58(3):353-63.
- 295 5. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and  
296 treatment strategies. *JCI Insight*. 2017;2(14).
- 297 6. Verma L, Chakravarti A, Gupta A, Prakash S. One day wonder: fast resolution of macular  
298 edema following intravitreal ranibizumab in retinal venous occlusions. *Indian J Ophthalmol*.  
299 2013;61(9):528-30.
- 300 7. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal  
301 aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*.  
302 2012;119(12):2537-48.
- 303 8. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and  
304 bevacizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2011;364(20):1897-  
305 908.
- 306 9. Jonas J, Paques M, Mones J, Glacet-Bernard A. Retinal vein occlusions. *Dev Ophthalmol*.  
307 2010;47:111-35.
- 308 10. Wroblewski JJ, Wells JA, 3rd, Adamis AP, Buggage RR, Cunningham ET, Jr., Goldbaum M, et  
309 al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. *Arch*  
310 *Ophthalmol*. 2009;127(4):374-80.
- 311 11. Khoramnia R, Figueroa MS, Hattenbach LO, Pavesio CE, Anderesi M, Schmouder R, et al.  
312 Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular  
313 AMD. *Graefes Arch Clin Exp Ophthalmol*. 2022;260(6):1843-56.
- 314 12. Kaiser PK, Cruess AF, Bogaert P, Khunti K, Kelly SP. Balancing risk in ophthalmic prescribing:  
315 assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines.  
316 *Graefes Arch Clin Exp Ophthalmol*. 2012;250(11):1563-71.
- 317 13. AJMC. FDA Approves Faricimab to Treat Wet AMD and DME USA: AJMC; 2022 [updated 1  
318 February 2022; cited 2022 07 November]. Available from: [https://www.ajmc.com/view/fda-  
319 approves-fariximab-to-treat-wet-amd-and-dme](https://www.ajmc.com/view/fda-approves-fariximab-to-treat-wet-amd-and-dme).
- 320 14. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding  
321 horizon beyond VEGF. *Eye (Lond)*. 2020;34(5):802-4.
- 322 15. Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik J-F, et al. TENAYA and  
323 LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-  
324 Related Macular Degeneration. *Ophthalmology Science*. 2021;1(4):100076.
- 325 16. Nicolò M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent  
326 targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. *Expert*  
327 *Opin Investig Drugs*. 2021;30(3):193-200.
- 328 17. Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the Treatment of  
329 Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. *Int J Mol*  
330 *Sci*. 2022;23(16).



*Anti-VEGF injections in Bhutan*

- 331 18. Nair AA, Finn AP, Sternberg P, Jr. Spotlight on Faricimab in the Treatment of Wet Age-  
332 Related Macular Degeneration: Design, Development and Place in Therapy. *Drug Des Devel Ther.*  
333 2022;16:3395-400.
- 334 19. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. IDIOPATHIC POLYPOIDAL CHOROIDAL  
335 VASCULOPATHY (IPCV). *RETINA.* 2012;32:1-8.
- 336 20. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green  
337 videoangiography of idiopathic polypoidal choroidal vasculopathy. *Retina (Philadelphia, Pa).*  
338 1995;15(2):100-10.
- 339 21. Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen S-J, Kim JE, et al. Polypoidal Choroidal  
340 Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria  
341 from the Asia-Pacific Ocular Imaging Society PCV Workgroup. *Ophthalmology.* 2021;128(3):443-52.
- 342 22. Sivakumar P, Vedachalam R, Kannusamy V, Odayappan A, Venkatesh R, Dhoble P, et al.  
343 Barriers in utilisation of low vision assistive products. *Eye (Lond).* 2020;34(2):344-51.
- 344 23. Rai BB, Morley MG, Bernstein PS, Maddess T. Pattern of vitreo-retinal diseases at the  
345 national referral hospital in Bhutan: a retrospective, hospital-based study. *BMC Ophthalmol.*  
346 2020;20(1).
- 347 24. Lewallen S, Courtright P. Gender and use of cataract surgical services in developing  
348 countries. *Bull World Health Organ.* 2002;80(4):300-3.
- 349 25. TIO. Bhutan's Saviour. *Bhutan News Service.* 2012.
- 350 26. Rai BB, Morley MG, Bernstein PS, Maddess T. Severity of age-related macular degeneration  
351 at first presentation in Bhutan: a 3-year national study. *BMC Ophthalmol.* 2022;22(1).
- 352 27. Giri BR, Sharma KP, Chapagai RN, Palzom D. Diabetes and hypertension in urban bhutanese  
353 men and women. *Indian J Community Med.* 2013;38(3):138-43.
- 354 28. WHO. Non-communicable diseases: Country profile 2018 2018 [cited 2022 12 May ].
- 355 29. Pelzom D, Isaakidis P, Oo MM, Gurung MS, Yangchen P. Alarming prevalence and clustering  
356 of modifiable noncommunicable disease risk factors among adults in Bhutan: a nationwide cross-  
357 sectional community survey. *BMC Public Health.* 2017;17.
- 358 30. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of  
359 published clinical data. *J Ophthalmol.* 2014;2014:724780.
- 360 31. Rai BB, Morley MG, Zangmo P, Tshering T, Khatiwara AN, Bernstein PS, et al. Retinal laser  
361 services in Bhutan: a 3-year national survey. *BMC Ophthalmol.* 2020;20(1):404.
- 362 32. Rai BB, Shresthra MK, Thapa R, Essex RW, Paudyal G, Maddess T. Pattern and presentation  
363 of vitreo-retinal diseases:an analysis of retrospective data at a tertiary eye care centre in Nepal. *Asia-  
364 Pac J Ophthalmol.* 2019;8(6):481-8.
- 365 33. Rai BB, Ashby RS, French AN, Maddess T. Rural-urban differences in myopia prevalence  
366 among myopes presenting to Bhutanese retinal clinical services: a 3-year national study. *Graefes  
367 Arch Clin Exp Ophthalmol.* 2021;259(3):613-21.
- 368 34. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of  
369 choroidal neovascularization in degenerative myopia. *Ophthalmology.* 1984;91(12):1573-81.
- 370 35. Fredette MJ, Giguere A, Anderson DR, Budenz DL, McSoley J. Comparison of Matrix with  
371 Humphrey Field Analyzer II with SITA. *Optom Vis Sci.* 2015;92(5):527-36.
- 372 36. Cheung CM, Yang E, Lee WK, Lee GK, Mathur R, Cheng J, et al. The natural history of  
373 polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. *Graefes Arch  
374 Clin Exp Ophthalmol.* 2015;253(12):2075-85.
- 375 37. Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, et al. Polypoidal choroidal  
376 vasculopathy and neovascular age-related macular degeneration: Same or different disease?  
377 *Progress in Retinal and Eye Research.* 2010;29(1):19-29.
- 378 38. Coscas G, Yamashiro K, Coscas F, De Benedetto U, Tsujikawa A, Miyake M, et al. Comparison  
379 of Exudative Age-related Macular Degeneration Subtypes in Japanese and French Patients:  
380 Multicenter Diagnosis With Multimodal Imaging. *American Journal of Ophthalmology.*  
381 2014;158(2):309-18.e2.

*Anti-VEGF injections in Bhutan*

- 382 39. Rai BB, Morley MG, Bernstein PS, Maddess T. Profile of age-related macular degeneration in  
383 Bhutan: Should screening be considered? *Investigative Ophthalmology & Visual Science*.  
384 2022;63(7):368 – F0199-368 – F.  
385 40. Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the  
386 general population. *PLoS One*. 2012;7(12):e50537.  
387 41. Brady CJ, Garg S. Telemedicine for Age-Related Macular Degeneration. *Telemed J E Health*.  
388 2020;26(4):565-8.